|
Applied Biosystems Expands Sequencing-based RNA Analysis Solutions Portfolio
27 August 2008
Applied Biosystems announced the development of a sequencing-based molecular tool for the genomic analysis of whole transcriptomes, the vast collection of RNAs transcribed from a genome. This technology provides detailed characterization of expressed protein-encoding genes, identifies many non-coding RNAs, and includes sample multiplexing capability.
|
|
|
|
XDx’s AlloMap® Gene Expression Test Cleared by FDA
27 August 2008
XDx, Inc. based in Brisbane, California has received market clearance from the U.S. Food and Drug Administration (FDA) for AlloMap® Molecular Expression Testing.
|
|
|
|
PREMIER Biosoft International completes final phase of software developement for DxTerity Diagnostics
27 August 2008
PREMIER Biosoft International today announced the successful completion and handover of the NEAT module to DxTerity. NEAT is an innovative genomic testing platform for the development of simple and affordable diagnostic tests. Software module access is available to DxTerity Diagnostic customers and partners.
|
|
|
|
Identification of miRNAs associated with gene regulation in Multiple Myeloma
26 August 2008
The role of microRNAs (miRNAs) in multiple myeloma (MM) has yet to be fully elucidated. To identify miRNAs that are potentially deregulated in MM, we investigated those mapping within transcription units, based on evidence that intronic miRNAs are frequently coexpressed with their
host genes. Host transcript expression values were monitored in a panel of 20 human MM cell lines (HMCLs) and focused on transcripts whose expression varied significantly across the dataset.
|
|
|
|
Novosom AG acquires exclusive license from Isis Pharmaceuticals, Inc. for CD40-targeted antisense inhibitors
26 August 2008
Novosom AG today announced that it has acquired an exclusive, worldwide license from Isis Pharmaceuticals to access certain antisense inhibitors targeting CD40 mRNA for a number of indications.
|
|
|
|
Location of genetic varation is key to potential role in disease
22 August 2008
Genetic variation is widely recognised as the key to survival and continued evolution of a species.
|
|
|
|
Regulus Therapeutics and Collaborators Publish Data on a Critical Role for miR-21 in Brain Tumors
20 August 2008
Data demonstrated that miR-21 is responsible for the regulation of multiple genes associated with glioma tumor cell death, migration and invasiveness.
|
|
|
|
MDRNA, Inc. Completes Exclusive License Agreement to RNAi Delivery Peptides
20 August 2008
The Company licenses intellectual property from the University of Michigan covering cationic peptides for enhanced delivery of nucleic acids.
|
|
|
|
M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics' MicroRNA-based Diagnostic Assay
18 August 2008
The study will correlate the results of Rosetta Genomics' microRNA-based CUP assay with diagnostic work conducted at M.D. Anderson Cancer Center.
|
|
|
|
Tiny Molecule Helps Control Blood-Vessel Development, Researchers Find
14 August 2008
Findings show that the development and repair of heart tissue and blood vessels is intimately tied to a tiny piece of RNA that is found nowhere else in the body.
|
|
|
|
Tekmira Pharmaceuticals Announces RNAi Research Collaboration with Bristol-Myers Squibb
14 August 2008
Bristol-Myers Squibb to use Tekmira's SNALP technology to deliver siRNAs to specific organs and tissues outside of the liver.
|
|
|
|
Designer RNA Fights High Cholesterol, Researchers Find
12 August 2008
Small RNA can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests.
|
|
|
|
Alnylam Forms Collaboration with Max Planck Institute to Investigate Biological Mechanisms for Cellular Uptake of RNAi Therapeutics
12 August 2008
Company to work with leading laboratory in cell trafficking field as part of continued commitment to advance research on delivery of RNAi therapeutics.
|
|
|
|
Researchers Discover Remnant of an Ancient ‘RNA World’
08 August 2008
Yale researchers describe some bacterial cells can swim, morph into new forms and even become dangerously virulent.
|
|
|
|
Putting microRNAs on the Stem Cell Map
08 August 2008
Whitehead researchers have now discovered how microRNAs fit into the map of embryonic stem cell circuitry.
|
|
|
|
Alnylam Awarded Continued Funding to Develop RNAi Therapeutics for Biological Threats
07 August 2008
Commitment for continued funding of $7.5 million supports Alnylam biodefense™ efforts and broad technology development.
|
|
|
|
Alnylam Consolidates Intellectual Property for RNA Activation
05 August 2008
Company completes exclusive license agreements with UT Southwestern Medical Center, UCSF, and the Salk Institute for Biological Studies.
|
|
|
|
Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
05 August 2008
The study is designed to evaluate the effectiveness of a siRNA therapeutic product based on Silence’s AtuRNAi technology in diabetic macular oedema.
|
|
|
|
Micro RNA Implicated as Molecular Factor in Alcohol Tolerance
04 August 2008
A new study now indicates that microRNA may influence the development of alcohol tolerance, a hallmark of alcohol abuse and dependence.
|
|
|
|
NuGEN Receives Patent for Global Nucleic Acid Amplification
04 August 2008
The patent describes a global whole genome amplification methodology using composite DNA/RNA primers able to anneal to multiple sites within the template polynucleotide.
|
|
|
|
Bio-Rad Describes Detailed Neuroblastoma Study Using qPCR Analysis
04 August 2008
The study uses examples from neuroblastoma research conducted at Bio-Rad and by researchers at Ghent University, Belgium.
|
|
|
|
Agilent Technologies Introduces miRNA Microarray Labelling and Hybridization Kit
04 August 2008
The new labelling and hybridization kit that are designed to simplify the protocol for running miRNA profiling experiments on Agilent oligonucleotide microarrays.
|
|
|